Early Hydrocortisone Versus Regular Treatment in Shock in Extremely Preterm Neonates - an Open Randomized Controlled Trial

The goal of this clinical trial is to determine the effectiveness of early use of hydrocortisone (since the diagnosis of shock) for its resolution within the first 72 hours in premature infants under 1,500 g. The main questions it aims to answer are: * Does the early use of hydrocortisone help solve shock in preterm infants under 1500 g faster than the standard treatment? * Does the early use of hydrocortisone help prevent death within the first seven days of presentation of shock in comparison to premature infants who receive regular treatment? Researchers will compare the early use of hydrocortisone plus the standard treatment to solve shock against just standard treatment. Participants will: * Be randomized to receive standard treatment for shock according to their neonatologist or this standard treatment plus hydrocortisone as soon as the diagnosis is done and treatment is started. * Be followed either until shock is solved or if they present death due to this event of shock.

NCT Number	NCT07248761
Lead Sponsor	Coordinación de Investigación en Salud, Mexico Collaborators: Instituto Mexicano del Seguro Social
Conditions	Shock, Preterm Birth Complication, Preterm Intraventricular Hemorrhage, Asphyxia Perinatal, Distress Respiratory Syndrome, Hyperglycaemia (Non Diabetic), Neonatal Sepsis, Early-Onset, Neonatal Sepsis, Late-Onset +3 more
Enrollment	76 participants
Start Date	2025-02-01
Primary Completion	2026-06-30 (estimated)
Study Completion	2026-07-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-25